| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
FDA lifted clinical hold on ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS) |
| 23 Oct 2026 |
8-K: Other Events
Disclaimer Aardvark Therapeutics, Inc. (“we”, “us,” “our” or the “Company”) does not (nor its respective affiliates, directors, members, officers, employees or agents) make any representation or warranty, express or implied, as to, and n... |
| 22 Oct 2026 |
8-K: Other Events
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data |
| 08 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche |
| 17 Aug 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On August 14, 2026, Aardvark Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 21,884,158 shares of the Company’s common stock outstanding as of June 18, 2026, the record date ... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps |
| 12 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 10, 2026, Aardvark Therapeutics, Inc. (the “Company”) entered into a retention bonus letter agreement with Nelson Sun, the Company’s Chief Financial Officer and Chief Operating Officer (the “Sun Retention Agreement”). Pursuant to... |
| 14 May 2026 |
8-K: Other Events
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate home... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 |
| 24 Mar 2026 |
8-K: Entry into a Material Definitive Agreement
On March 23, 2026, Aardvark Therapeutics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co., as sales agent (the “Agent”), pursuant to which the Company may,... |
| 23 Mar 2026 |
8-K: Results of Operations and Financial Condition
Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 |
| 27 Feb 2026 |
8-K: Other Events
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) – Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathway... |
| 12 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
This letter (the “Agreement”) sets forth the terms and conditions of your separation from Aardvark Therapeutics, Inc. (the “Company”) in connection with your termination of employment. |
| 10 Feb 2026 |
8-K: Other Events
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome |
| 12 Jan 2026 |
8-K: Other Events
Disclaimer Aardvark Therapeutics, Inc. (the “Company”) does not (nor its respective affiliates, directors, members, officers, employees or agents) make any representation or warranty, express or implied, as to, and no reliance should be ... |
| 10 Dec 2025 |
8-K: Other Events
Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) |
| 06 Nov 2025 |
8-K: Other Events
Disclaimer Aardvark Therapeutics, Inc. (the “Company”) does not (nor their respective affiliates, directors, members, officers, employees or agents) make any representation or warranty, express or implied, as to, and no reliance should b... |
| 04 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s obesity treatment landscape |
| 09 Oct 2025 |
8-K: Other Events
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome |
Loading...